Qiagen N.V. (QGEN) Earnings Call Transcripts

Qiagen N.V.'s Latest Earnings Call - June 24, 2026

In the Q2 2026 earnings call, Qiagen N.V. reported a revenue of $2.09 billion for the fiscal year 2025, reflecting a 6% increase year-over-year, while adjusted earnings per share (EPS) rose to $2.38, exceeding prior guidance. However, management lowered revenue guidance for 2026 to a growth range of 1% to 2% due to unexpected declines in tuberculosis testing demand. The company also announced a 40% increase in its dividend to $0.35 per share, signaling a commitment to returning capital to shareholders despite the challenging market environment.

Reported metrics

Guidance from management

Management lowered its revenue growth guidance for 2026 to a range of 1% to 2% and adjusted EPS guidance to $2.43, citing a challenging market environment and specific declines in tuberculosis testing.

What management said

Thank you, Thierry. Before I invite Roland to come up to the podium, I'd like to say that what we'd like to do after we have the presentation of Roland, is at that time, we'll take all your questions for all the agenda items that are meeting. We find this approach best serves you in providing an opportunity to discuss a wide range of topics. Then I will briefly introduce the agenda items, which we're required to do, ...

Okay. Thank you. So let's see, we have a number of questions. Let's make sure we can walk through all of these. The first question is pretty straightforward, and that is why did we schedule the meeting at 9 a.m. It's my understanding, Thierry and Roland, that it's been our practice, running the AGM at 9 a.m. That's good feedback. We appreciate that. But it has been our practice, starting at 9 o'clock for a number of ...

What analysts pressed on

Analysts expressed concerns regarding the lowered revenue guidance and the impact of market conditions on future growth. There were also inquiries about the sustainability of the dividend increase amidst these challenges.

Main topics on the call

• Revenue Performance — Qiagen reported $2.09 billion in sales for 2025, a 6% increase year-over-year, which was at the high end of their guidance. Management noted, 'We reached the high end of our sales outlook and exceeded the adjusted earnin...
• Guidance Revision — Management revised its 2026 revenue growth guidance down to 1% to 2%, citing a slowdown in tuberculosis testing as a significant factor. They stated, 'We were taken, to a certain extent, by surprise, by the complete slow...
• Dividend Increase — Qiagen announced a 40% increase in its annual dividend to $0.35 per share, reflecting a commitment to returning capital to shareholders. Roland Sackers mentioned, 'We are proposing a 40% increase in our annual dividend.'
• Profitability Improvement — The adjusted operating income margin improved to 29.5%, up from 28.7% in the previous year, indicating effective cost management. Roland noted, 'We again delivered improved profitability as the adjusted operating income ...

Read the full Qiagen N.V. transcript (June 24, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 95 Qiagen N.V. earnings call transcripts on record, spanning January 13, 2020 to June 24, 2026. Based on this history, Qiagen N.V. reports quarterly. The most recent call on file is dated June 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

QGEN

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

95

First call

January 13, 2020

Most recent

June 24, 2026

Reporting cadence

quarterly